Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Reports Updated Results from Phase I trial of anti-PD-L1 mAb in NSCLC

publication date: May 27, 2020

Suzhou CStone Pharma released updated efficacy data from a Phase I trial of its anti-PD-L1 mAb as a first-line treatment for non-small cell lung cancer (NSCLC). CS1001 showed objective response rates of 47.6% in the non-squamous NSCLC arm and 75% in the squamous cohort with a benign safety profile. CS1001 was discovered using Ligand's fully human OmniAb platform at WuXi Biologics. In China, CS1001 is currently being tested in a Phase Ib study, two pivotal Phase II trials and three Phase III tests in several tumor types, plus a US Phase I bridging study. More details....

Stock Symbols: (HK: 2616) (NSDQ: LGND) (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.